liver cancer
Conditions
Interventions
TACE combined with TKI plus PD-1 immunotherapy group:N/A
TKI plus PD-1 group:N/A
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Clinical or pathological diagnosis of primary liver cancer; 2) BCLC-C stage liver cancer; 3) Both genders, aged 18-75; 4) Received targeted plus immunotherapy or TACE combined with targeted plus immunotherapy; 5) Complete baseline imaging and laboratory data; 6) Completed at least one imaging and clinical assessment within 3 months of starting initial treatment; 7) Has complete follow-up information.
Exclusion criteria
Exclusion criteria: 1) Presence of malignant tumors in other systems of the body; 2) Impaired vital organ function, such as the heart, brain, or kidneys; 3) History of liver function classified as Child-Pugh C prior to treatment initiation, along with significant ascites, hepatic encephalopathy, or a history of esophageal variceal bleeding; 4) No prior treatment with TACE, ablation therapy, targeted therapy, immunotherapy, biologic therapy, radiation therapy, or surgical intervention before treatment initiation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Reaction Rate;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Edverse Events above 3-grade;progression-free survival; | — |
Countries
China
Contacts
Public ContactFeng Duan
Chinese PLA General Hospital
Outcome results
None listed